Pytel Dariusz, Seyb Kathleen, Liu Min, Ray Soumya S, Concannon John, Huang Mickey, Cuny Gregory D, Diehl J Alan, Glicksman Marcie A
The Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA.
Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA.
J Biomol Screen. 2014 Aug;19(7):1024-34. doi: 10.1177/1087057114525853. Epub 2014 Mar 5.
PERK is serine/threonine kinase localized to the endoplasmic reticulum (ER) membrane. PERK is activated and contributes to cell survival in response to a variety of physiological stresses that affect protein quality control in the ER, such as hypoxia, glucose depravation, increased lipid biosynthesis, and increased protein translation. Pro-survival functions of PERK are triggered by such stresses, suggesting that development of small-molecule inhibitors of PERK may be efficacious in a variety of disease scenarios. Hence, we have conducted a detailed enzymatic characterization of the PERK kinase to develop a high-throughput-screening assay (HTS) that will permit the identification of small-molecule PERK inhibitors. In addition to establishing the K(m) of PERK for both its primary substrate, eIF2α, and for adenosine triphosphate, further mechanistic studies revealed that PERK targets its substrate via either a random/steady-state ordered mechanism. For HTS, we developed a time-resolved fluorescence resonance energy transfer-based assay that yielded a robust Z' factor and percent coefficient of variation value, enabling the successful screening of 79,552 compounds. This approach yielded one compound that exhibited good in vitro and cellular activity. These results demonstrate the validity of this screen and represent starting points for drug discovery efforts.
蛋白激酶R(PERK)是一种定位于内质网(ER)膜的丝氨酸/苏氨酸激酶。在应对多种影响内质网中蛋白质质量控制的生理应激时,如缺氧、葡萄糖剥夺、脂质生物合成增加和蛋白质翻译增加,PERK被激活并有助于细胞存活。PERK的促生存功能由这些应激触发,这表明开发PERK的小分子抑制剂在多种疾病情况下可能有效。因此,我们对PERK激酶进行了详细的酶学表征,以开发一种高通量筛选分析方法(HTS),该方法将能够鉴定小分子PERK抑制剂。除了确定PERK对其主要底物真核翻译起始因子2α(eIF2α)和三磷酸腺苷的米氏常数(Km)外,进一步的机制研究表明,PERK通过随机/稳态有序机制靶向其底物。对于高通量筛选,我们开发了一种基于时间分辨荧光共振能量转移的分析方法,该方法产生了稳健的Z'因子和变异系数百分比值,从而能够成功筛选79552种化合物。这种方法产生了一种在体外和细胞实验中均表现出良好活性的化合物。这些结果证明了该筛选方法的有效性,并为药物研发工作提供了起点。